For people diagnosed with small cell lung cancer (SCLC), the conversation about clinical trials should happen at the very first appointment, not after other treatments have failed. That is the key message from Dr. Ashish Saxena, Chief of Thoracic Medical Oncology at Weill Cornell Medicine, who emphasizes that some trials are only available before treatment begins, while others are testing promising therapies as first-line options. For a fast-moving cancer like SCLC, timing is critical.
SCLC has historically had few treatment options, but the landscape is changing rapidly. According to Dr. Saxena, emerging treatments now involve immunotherapy, where the immune system attacks the cancer, and antibody-drug conjugates, which target specific proteins in small cell cancer and deliver chemotherapy directly to the tumor rather than free-flowing chemotherapy throughout the bloodstream. Researchers are also learning more about the biology of SCLC and how certain patients may respond better to specific drugs. “There are a lot of changes going on in the landscape today, more than we've seen for a very long time,” says Dr. Saxena. “So, all of these things should give patients a lot of hope when they are diagnosed with small cell lung cancer.”
This progress is not just about extending life; it is also about improving how patients feel. Clinical trials increasingly track patient-reported outcomes such as fatigue, breathing problems, pain, and emotional well-being, alongside traditional measures like tumor shrinkage. “The goal is to have meaningful time, not just more time,” Dr. Saxena explains. These outcomes can provide early clues about whether a treatment is working—a cough may improve, breathing may become easier, or energy may return—even before the next scan.
Patients themselves play a vital role in their care by speaking up about side effects and changes in how they feel. This feedback helps doctors adjust medications or dosages and better manage symptoms, potentially allowing patients to stay on treatment longer. In clinical trials, it also helps researchers understand the therapy's impact on daily life. Wendy Brooks, who is living with small cell lung cancer and is a member of the LCFA's Voices of Hope Speakers Bureau, finds the pace of change encouraging. “I'm more hopeful today than I have ever been,” says Brooks.
The message for patients is clear: do not wait to ask about clinical trials. Ask early, ask before treatment begins, and keep asking as the treatment journey continues. That one question—“Is there a clinical trial that might be right for me?”—could open a door you didn’t know was there. To hear the full conversation between Wendy Brooks and Dr. Ashish Saxena on the Hope With Answers podcast and learn more about small cell lung cancer research, clinical trials, and treatment, visit LCFAmerica.org. The Lung Cancer Foundation of America (LCFA) is dedicated to dramatically improving survival rates and quality of life for people diagnosed with lung cancer through funding innovative research, amplifying patient stories, and raising awareness.
